A new study is investigating the safety and best dosage of removing blood clots in children with acute ischemic stroke. According to James Grotta, M.D., professor and the Roy M. & Phyllis Gough Huffington Distinguished Chair in the Department of Neurology at the UTHealth Medical School, “No one knows how kids who have suffered a stroke will respond to this type of treatment and we don’t know what the correct dosage might be, so this will look at various doses. Very few kids have ischemic strokes and they look very different from strokes in adults. We know kids recover quicker and better than adults because a child’s brain has more capability for recovery.”
One form of stroke, known as hemorrhagic stroke, occurs when a weak blood vessel breaks and bleeds into the brain. However, ischemic stroke is when a blood vessel is blocked by a clot. Ischemic stroke is more common in adults (80 percent), it occurs in about 50 percent of pediatric strokes. The probability of both forms of stroke from birth to age 18 runs around 11 in 100,000 children. Stroke happens to be one of the top 10 causes of death in children. Factors that put children at greater risk include sickle cell disease, clotting and cardiac disorders, arterial disease and meningitis.
The current study is listed as Thrombolysis in Pediatric Stroke (TIPS). Children under investigation include ages 2 to 17 and they will be administered one of three doses of tissue plasminogen activator (tPA) within four and a half hours after presentation of ischemic stroke symptoms.
If you’re interested in further information, visit http://www.clinicaltrials.gov/ct2/show/NCT01591096.
Read more UTHealth news here:
[feed url=”http://bionews-tx.com/news/news-category/university-of-texas-health-science-center/feed” number=”5″ ]